Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estriol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 6/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | SHBG | P04278 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 1.00 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | STS | P08842 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estriol SCHEMBL12180048 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL14373308 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL4896486 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL7004654 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL13123063 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL23743979 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Epiestriol SCHEMBL221084 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL223226 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL8941750 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL2001122 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008147640-A2 | HORMONE REPLACEMENT THERAPY | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-12-04 | — | — | WO | claimed |
| US-20080293683-A1 | Hormone Replacement Therapy | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-11-27 | — | — | US | claimed |
| US-12319651-B2 | Crystalline forms and methods of producing crystalline forms of a compound | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2025-06-03 | — | — | US | disclosed |
| US-20220204448-A1 | CRYSTALLINE FORMS AND METHODS OF PRODUCING CRYSTALLINE FORMS OF A COMPOUND | LIGAND PHARMACEUTICALS INC. | 2022-06-30 | — | — | US | disclosed |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| CN-114096522-A | Crystalline forms of a compound and methods of making crystalline forms of a compound | 利亘制药公司 | 2022-02-25 | — | — | CN | disclosed |
| EP-3956309-A1 | CRYSTALLINE FORMS AND METHODS OF PRODUCING CRYSTALLINE FORMS OF A COMPOUND | Ligand Pharmaceuticals Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-10874638-B2 | Methods and compositions for modulating hormone levels | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200361866-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-11-19 | — | — | US | disclosed |
| WO-2020214834-A1 | CRYSTALLINE FORMS AND METHODS OF PRODUCING CRYSTALLINE FORMS OF A COMPOUND | LIGAND PHARMACEUTICALS INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-10730831-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2020-08-04 | — | — | US | disclosed |
| EP-1149838-A1 | Estriol substantially free of 16alpha, 17alpha-estra-1,3,5(10)-triene-3,16,17-triol | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2001-10-31 | — | — | EP | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| US-6086915-A | HEATING THE SOLUBILIZING EMULSIFIER, ADDING SOLVENT AND ONE OR MORE PHOSPHOLIPID SURFACTANTS, DISSOLVING IN THIS SOLUTION ONE OR MORE HYDROPHOBIC PHYTOCHEMICALS, ADDING ENCAPSULATORS, FORMING MICROEMULSION, SPRAY DRYING THE SOLUTION | BIORESPONSE L.L.C. (US) | 2000-07-11 | — | — | US | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
| EP-0182104-B1 | HALOGEN LABELED COMPOUNDS INCLUDING ESTRADIOL DERIVATIVES, THEIR SYNTHETIC INTERMEDIATES AND THE SYNTHESES THEREOF | BIO-MEDICAL RESEARCH LABORATORIES, INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| US-4855125-A | Iodinated estradiols, intermediate products and methods of production | BIO-MEDICAL RESEARCH LABORATORIES (US) | 1989-08-08 | — | — | US | disclosed |
| US-4659517-A | Halogen labeled compounds including estradiol derivatives, their synthetic intermediates and the syntheses thereof | BIO-MEDICAL RESEARCH LABORATORIES, INC. (US) | 1987-04-21 | — | — | US | disclosed |
| EP-0182104-A1 | Halogen labeled compounds including estradiol derivatives, their synthetic intermediates and the syntheses thereof | BIO-MEDICAL RESEARCH LABORATORIES, INC. (US) | 1986-05-28 | — | — | EP | disclosed |
| US-3939186-A | Process for producing ethers of steroids | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204448-A1 | CRYSTALLINE FORMS AND METHODS OF PRODUCING CRYSTALLINE FORMS OF A COMPOUND | RCC1, CYP2F1, CENPE | ESR1 4562/4885ESR2 2726/4885LMNA 154/4885 |
| US-20200361866-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | ESR1 29/4885ESR2 21/4885LMNA 3992/4885 |
| US-20080293683-A1 | Hormone Replacement Therapy | ESR2, SHBG, ESRRG | ESR1 4/4885ESR2 1/4885LMNA 4487/4885 |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | ESR1 34/4885ESR2 17/4885LMNA 4044/4885 |
| US-10874638-B2 | Methods and compositions for modulating hormone levels | SHBG, ESRRB, ESRRA | ESR1 9/4885ESR2 6/4885LMNA 1701/4885 |
| US-10730831-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | ESR1 34/4885ESR2 17/4885LMNA 4044/4885 |
| US-12319651-B2 | Crystalline forms and methods of producing crystalline forms of a compound | RCC1, CYP2F1, CENPE | ESR1 4562/4885ESR2 2726/4885LMNA 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.